National Research Co. (NASDAQ:NRC) Major Shareholder Sells $788,966.64 in Stock

Share on StockTwits

National Research Co. (NASDAQ:NRC) major shareholder Amandla Mk Trust sold 12,198 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.68, for a total transaction of $788,966.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Amandla Mk Trust also recently made the following trade(s):

  • On Thursday, August 15th, Amandla Mk Trust sold 19,000 shares of National Research stock. The stock was sold at an average price of $64.72, for a total transaction of $1,229,680.00.

NASDAQ NRC opened at $64.55 on Thursday. The company has a fifty day simple moving average of $37.97 and a two-hundred day simple moving average of $31.90. The stock has a market cap of $1.60 billion, a P/E ratio of 62.07 and a beta of 0.80. National Research Co. has a 12-month low of $35.58 and a 12-month high of $68.86. The company has a current ratio of 0.62, a quick ratio of 0.62 and a debt-to-equity ratio of 1.24.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Quantamental Technologies LLC increased its stake in shares of National Research by 125.2% in the second quarter. Quantamental Technologies LLC now owns 743 shares of the company’s stock worth $43,000 after acquiring an additional 413 shares during the period. Bank of Montreal Can acquired a new stake in shares of National Research during the 2nd quarter worth about $59,000. Legal & General Group Plc boosted its stake in shares of National Research by 35.0% during the 4th quarter. Legal & General Group Plc now owns 2,118 shares of the company’s stock worth $81,000 after purchasing an additional 549 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of National Research by 17.8% during the 2nd quarter. Advisor Group Inc. now owns 2,263 shares of the company’s stock worth $131,000 after purchasing an additional 342 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of National Research by 10,395.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,309 shares of the company’s stock worth $89,000 after purchasing an additional 2,287 shares during the last quarter. 36.86% of the stock is owned by institutional investors and hedge funds.

About National Research

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Further Reading: How Investors Can Profit from Options Trading

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRC)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades Dunkin Brands Group  to Hold
Zacks Investment Research Downgrades Dunkin Brands Group to Hold
Esperion Therapeutics  Given New $70.00 Price Target at Stifel Nicolaus
Esperion Therapeutics Given New $70.00 Price Target at Stifel Nicolaus
Zacks Investment Research Upgrades First Community  to Hold
Zacks Investment Research Upgrades First Community to Hold
ConnectOne Bancorp  Stock Rating Upgraded by Zacks Investment Research
ConnectOne Bancorp Stock Rating Upgraded by Zacks Investment Research
ValuEngine Lowers Cue Biopharma  to Hold
ValuEngine Lowers Cue Biopharma to Hold
Chimerix  Upgraded by Zacks Investment Research to Hold
Chimerix Upgraded by Zacks Investment Research to Hold


© 2006-2019 Ticker Report